Shopping Cart 0
Cart Subtotal
USD 0

Abzena Plc (ABZA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Abzena Plc (Abzena), formerly Polytherics Group Ltd, is a life science company that provides complementary services and technologies to enable the selection, development and manufacture of biopharmaceuticals products based on antibodies and other proteins. The company's technologies include antibody discovery and candidate screening, immunology and immunogenicity assessment, manufacture of payload linkers and antibody drug conjugates, development of manufacturing cell lines and process development, and others. Abzena provides its services to biopharmaceutical companies, public and private biotech companies and academic groups, among others. It has its presence in the UK and the US. Abzena is headquartered in Cambridge, the UK.

Abzena Plc (ABZA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Abzena Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Abzena Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Abzena Plc, Medical Devices Deals, 2012 to YTD 2018 11

Abzena Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Abzena Plc, Pharmaceuticals & Healthcare, Deal Details 14

Venture Financing 14

Abzena Raises Funds through Venture Financing 14

Partnerships 16

Abzena Enters into Agreement with Enleofen Bio 16

Abzena Partners with UGA Biopharma 17

Abzena and Baylor Scott & White Research Institute Form Joint Venture 18

Abzena Enters into Agreement with Apitope 19

Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 20

PolyTherics Enters into Agreement with Alpha Cancer to Produce Tumor Targeting Drug Conjugate Pact 21

Antitope Enters Into Research Agreement With Annexon For Therapeutic Antibodies 22

Tube Pharma Enters into Co-Development Agreement with PolyTherics for Antibody Drug Conjugates 23

Antitope Enters Into Research Agreement With ChemomAb For Composite Human Antibodies 24

Antitope Enters Into Co-Development Agreement With Research Corporation Technologies For Therapeutic Protein 25

Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 26

Antitope Enters Into Research Agreement With NeuroPhage Pharma 27

Biotecnol Enters Into Co-Development Agreement With PolyTherics For Tribody Drug Conjugates 28

PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 29

Licensing Agreements 30

Tmunity Therapeutics Enters into Licensing Agreement with Abzena 30

Telix Pharma Enters into Licensing Agreement with Abzena 31

OBI Pharma Enters into Licensing Agreement with Abzena 32

Abzena Enters into Licensing Agreement for ThioBridge 33

Trieza Therapeutics Enters into Licensing Agreement with Abzena 34

ProtAb Enters into License Agreement with Antitope 35

PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor IX 36

PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor VIIa 37

Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 38

PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Technology 39

Equity Offering 40

Abzena Raises USD31 Million in Private Placement of Shares 40

Abzena Raises Funds through Private Placement of Shares upon Exercise of Warrants 41

Abzena Raises USD31.8 Million in Private Placement of Shares 42

Abzena Completes IPO 43

Acquisition 44

Astro Bidco to Acquire Abzena 44

Abzena Acquires The Chemistry Research Solution for USD15 Million 46

Abzena Acquires PacificGMP 47

PolyTherics Acquires Antitope For USD 20.7 Million 49

Abzena Plc-Key Competitors 50

Abzena Plc-Key Employees 51

Abzena Plc-Locations And Subsidiaries 52

Head Office 52

Other Locations & Subsidiaries 52

Joint Venture 53

Recent Developments 54

Strategy And Business Planning 54

Jan 05, 2018: Abzena Takes on New Facilities in Cambridge, UK and San Diego 54

Financial Announcements 55

Apr 16, 2018: Abzena: Pre-Close Period Trading Update FY2018 55

Dec 12, 2017: Half year results: Growth strategy progressing 57

Jun 13, 2017: Abzena Announces Full year results: integration and growth seen across the Group, with 41% underlying increase in revenues 58

Feb 21, 2017: Abzena: Trading and business update 59

Corporate Communications 61

Oct 16, 2018: Abzena announces the appointment of Jonathan Goldman, MD as Chief Executive Officer 61

Legal and Regulatory 62

Mar 05, 2018: Abzena: Settlement of claim 62

Government and Public Interest 63

Mar 02, 2017: Abzena, UCL secure GBP3.5m grant from MRC for autoimmune therapy research 63

Product News 64

Mar 06, 2017: 'Abzena inside' product for neurodegenerative conditions moves into Phase II trial 64

Other Significant Developments 65

Mar 26, 2018: Facility Remodelling Completed for Abzena's New Antibody-Drug Conjugate GMP Manufacturing Suite 65

Nov 14, 2017: Novel Antibodies against a Ground-Breaking New Target for the Treatment of Cardiovascular Fibrosis Developed by Enleofen Bio, with Support from Abzena, Featured in 'Nature' Article 66

Appendix 67

Methodology 67

About GlobalData 67

Contact Us 67

Disclaimer 67


List Of Figure

List of Figures

Abzena Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Abzena Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Abzena Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Abzena Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Abzena Plc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Abzena Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Abzena Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Abzena Plc, Deals By Therapy Area, 2012 to YTD 2018 10

Abzena Plc, Medical Devices Deals, 2012 to YTD 2018 11

Abzena Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Abzena Raises Funds through Venture Financing 14

Abzena Enters into Agreement with Enleofen Bio 16

Abzena Partners with UGA Biopharma 17

Abzena and Baylor Scott & White Research Institute Form Joint Venture 18

Abzena Enters into Agreement with Apitope 19

Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 20

PolyTherics Enters into Agreement with Alpha Cancer to Produce Tumor Targeting Drug Conjugate Pact 21

Antitope Enters Into Research Agreement With Annexon For Therapeutic Antibodies 22

Tube Pharma Enters into Co-Development Agreement with PolyTherics for Antibody Drug Conjugates 23

Antitope Enters Into Research Agreement With ChemomAb For Composite Human Antibodies 24

Antitope Enters Into Co-Development Agreement With Research Corporation Technologies For Therapeutic Protein 25

Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 26

Antitope Enters Into Research Agreement With NeuroPhage Pharma 27

Biotecnol Enters Into Co-Development Agreement With PolyTherics For Tribody Drug Conjugates 28

PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 29

Tmunity Therapeutics Enters into Licensing Agreement with Abzena 30

Telix Pharma Enters into Licensing Agreement with Abzena 31

OBI Pharma Enters into Licensing Agreement with Abzena 32

Abzena Enters into Licensing Agreement for ThioBridge 33

Trieza Therapeutics Enters into Licensing Agreement with Abzena 34

ProtAb Enters into License Agreement with Antitope 35

PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor IX 36

PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor VIIa 37

Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 38

PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Technology 39

Abzena Raises USD31 Million in Private Placement of Shares 40

Abzena Raises Funds through Private Placement of Shares upon Exercise of Warrants 41

Abzena Raises USD31.8 Million in Private Placement of Shares 42

Abzena Completes IPO 43

Astro Bidco to Acquire Abzena 44

Abzena Acquires The Chemistry Research Solution for USD15 Million 46

Abzena Acquires PacificGMP 47

PolyTherics Acquires Antitope For USD 20.7 Million 49

Abzena Plc, Key Competitors 50

Abzena Plc, Key Employees 51

Abzena Plc, Other Locations 52

Abzena Plc, Subsidiaries 52

Abzena Plc, Joint Venture 53

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Abzena Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Abzena Plc (Abzena), formerly Polytherics Group Ltd, is a life science company that provides complementary services and technologies to enable the selection, development and manufacture of biopharmaceuticals products based on antibodies and other proteins. The company's technologies include antibody discovery and candidate screening, immunology and immunogenicity assessment, manufacture of payload linkers and antibody drug conjugates, development of manufacturing cell lines and process development, and others. Abzena provides its services to biopharmaceutical companies, public and private biotech companies and academic groups, among others. It has its presence in the UK and the US. Abzena is headquartered in Cambridge, the UK.

Abzena Plc (ABZA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Abzena Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Abzena Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Abzena Plc, Medical Devices Deals, 2012 to YTD 2018 11

Abzena Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Abzena Plc, Pharmaceuticals & Healthcare, Deal Details 14

Venture Financing 14

Abzena Raises Funds through Venture Financing 14

Partnerships 16

Abzena Enters into Agreement with Enleofen Bio 16

Abzena Partners with UGA Biopharma 17

Abzena and Baylor Scott & White Research Institute Form Joint Venture 18

Abzena Enters into Agreement with Apitope 19

Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 20

PolyTherics Enters into Agreement with Alpha Cancer to Produce Tumor Targeting Drug Conjugate Pact 21

Antitope Enters Into Research Agreement With Annexon For Therapeutic Antibodies 22

Tube Pharma Enters into Co-Development Agreement with PolyTherics for Antibody Drug Conjugates 23

Antitope Enters Into Research Agreement With ChemomAb For Composite Human Antibodies 24

Antitope Enters Into Co-Development Agreement With Research Corporation Technologies For Therapeutic Protein 25

Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 26

Antitope Enters Into Research Agreement With NeuroPhage Pharma 27

Biotecnol Enters Into Co-Development Agreement With PolyTherics For Tribody Drug Conjugates 28

PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 29

Licensing Agreements 30

Tmunity Therapeutics Enters into Licensing Agreement with Abzena 30

Telix Pharma Enters into Licensing Agreement with Abzena 31

OBI Pharma Enters into Licensing Agreement with Abzena 32

Abzena Enters into Licensing Agreement for ThioBridge 33

Trieza Therapeutics Enters into Licensing Agreement with Abzena 34

ProtAb Enters into License Agreement with Antitope 35

PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor IX 36

PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor VIIa 37

Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 38

PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Technology 39

Equity Offering 40

Abzena Raises USD31 Million in Private Placement of Shares 40

Abzena Raises Funds through Private Placement of Shares upon Exercise of Warrants 41

Abzena Raises USD31.8 Million in Private Placement of Shares 42

Abzena Completes IPO 43

Acquisition 44

Astro Bidco to Acquire Abzena 44

Abzena Acquires The Chemistry Research Solution for USD15 Million 46

Abzena Acquires PacificGMP 47

PolyTherics Acquires Antitope For USD 20.7 Million 49

Abzena Plc-Key Competitors 50

Abzena Plc-Key Employees 51

Abzena Plc-Locations And Subsidiaries 52

Head Office 52

Other Locations & Subsidiaries 52

Joint Venture 53

Recent Developments 54

Strategy And Business Planning 54

Jan 05, 2018: Abzena Takes on New Facilities in Cambridge, UK and San Diego 54

Financial Announcements 55

Apr 16, 2018: Abzena: Pre-Close Period Trading Update FY2018 55

Dec 12, 2017: Half year results: Growth strategy progressing 57

Jun 13, 2017: Abzena Announces Full year results: integration and growth seen across the Group, with 41% underlying increase in revenues 58

Feb 21, 2017: Abzena: Trading and business update 59

Corporate Communications 61

Oct 16, 2018: Abzena announces the appointment of Jonathan Goldman, MD as Chief Executive Officer 61

Legal and Regulatory 62

Mar 05, 2018: Abzena: Settlement of claim 62

Government and Public Interest 63

Mar 02, 2017: Abzena, UCL secure GBP3.5m grant from MRC for autoimmune therapy research 63

Product News 64

Mar 06, 2017: 'Abzena inside' product for neurodegenerative conditions moves into Phase II trial 64

Other Significant Developments 65

Mar 26, 2018: Facility Remodelling Completed for Abzena's New Antibody-Drug Conjugate GMP Manufacturing Suite 65

Nov 14, 2017: Novel Antibodies against a Ground-Breaking New Target for the Treatment of Cardiovascular Fibrosis Developed by Enleofen Bio, with Support from Abzena, Featured in 'Nature' Article 66

Appendix 67

Methodology 67

About GlobalData 67

Contact Us 67

Disclaimer 67


List Of Figure

List of Figures

Abzena Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Abzena Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Abzena Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Abzena Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Abzena Plc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Abzena Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Abzena Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Abzena Plc, Deals By Therapy Area, 2012 to YTD 2018 10

Abzena Plc, Medical Devices Deals, 2012 to YTD 2018 11

Abzena Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Abzena Raises Funds through Venture Financing 14

Abzena Enters into Agreement with Enleofen Bio 16

Abzena Partners with UGA Biopharma 17

Abzena and Baylor Scott & White Research Institute Form Joint Venture 18

Abzena Enters into Agreement with Apitope 19

Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 20

PolyTherics Enters into Agreement with Alpha Cancer to Produce Tumor Targeting Drug Conjugate Pact 21

Antitope Enters Into Research Agreement With Annexon For Therapeutic Antibodies 22

Tube Pharma Enters into Co-Development Agreement with PolyTherics for Antibody Drug Conjugates 23

Antitope Enters Into Research Agreement With ChemomAb For Composite Human Antibodies 24

Antitope Enters Into Co-Development Agreement With Research Corporation Technologies For Therapeutic Protein 25

Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 26

Antitope Enters Into Research Agreement With NeuroPhage Pharma 27

Biotecnol Enters Into Co-Development Agreement With PolyTherics For Tribody Drug Conjugates 28

PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 29

Tmunity Therapeutics Enters into Licensing Agreement with Abzena 30

Telix Pharma Enters into Licensing Agreement with Abzena 31

OBI Pharma Enters into Licensing Agreement with Abzena 32

Abzena Enters into Licensing Agreement for ThioBridge 33

Trieza Therapeutics Enters into Licensing Agreement with Abzena 34

ProtAb Enters into License Agreement with Antitope 35

PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor IX 36

PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor VIIa 37

Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 38

PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Technology 39

Abzena Raises USD31 Million in Private Placement of Shares 40

Abzena Raises Funds through Private Placement of Shares upon Exercise of Warrants 41

Abzena Raises USD31.8 Million in Private Placement of Shares 42

Abzena Completes IPO 43

Astro Bidco to Acquire Abzena 44

Abzena Acquires The Chemistry Research Solution for USD15 Million 46

Abzena Acquires PacificGMP 47

PolyTherics Acquires Antitope For USD 20.7 Million 49

Abzena Plc, Key Competitors 50

Abzena Plc, Key Employees 51

Abzena Plc, Other Locations 52

Abzena Plc, Subsidiaries 52

Abzena Plc, Joint Venture 53

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Abzena Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.